Choate represented Perceptive Xontogeny Venture Fund as the lead investor in the financing.
Forge Biologics Holdings, LLC completed a $40M Series A financing.
The proceeds of this financing will be used to expand AAV manufacturing CDMO capabilities in 2020, with cGMP production capacity available by mid-2021, and for the development of a novel gene therapy pipeline.
Forge Biologics Holdings, LLC is a viral vector gene therapy manufacturing and development company with the dual platform of CDMO capabilities and the development of proprietary gene therapy products.
Choate represented Perceptive Xontogeny Venture Fund with a team consisting of Partner Kevin M. Tormey (Picture) and Associate Dana W. Spigelman.
Involved fees earner: Dana Spigelman – Choate; Kevin Tormey – Choate;
Law Firms: Choate;
Clients: Perceptive Xontogeny Venture Fund;
